AI Gait Analysis Firm AIT Studio Secures Funding

South Korean AI innovator, AIT Studio, has successfully closed a pre-Series A funding round, signaling strong investor confidence in its advanced gait analysis technology. The capital infusion, led by Bluepoint Partners through its specialized 'InBody Like Bluepoint' fund, with participation from East Gate Partners and MAGNA Investment, will fuel the company's ambitious global expansion plans. This funding marks a significant valuation jump for AIT Studio, more than doubling its worth within a year of its initial seed financing.

At the heart of AIT Studio's offering is MEDISTEP, a sophisticated computer vision system that performs markerless gait analysis using standard mobile cameras. This approach eliminates the need for cumbersome sensors or wearable devices, offering a cost-effective and accessible solution. The platform can generate over 40 detailed gait indicators in under a minute, achieving remarkable accuracy comparable to traditional motion capture methods while reducing costs by more than 90%.

The clinical validation of MEDISTEP is already robust, with adoption by eight major university hospitals in South Korea, including the prestigious Asan Medical Center, within its first year of commercialization. Beyond acute care settings, the technology is also being deployed in public health facilities, elder care centers, and senior fitness programs nationwide, demonstrating its broad applicability in improving health outcomes across diverse populations.

With European CE-MDR certification secured earlier this year, AIT Studio is strategically positioned for entry into five key Asian markets. The company is also leveraging its partnership with InBody, a leader in body composition analysis, to target expansion into Japan and North America. Future development will see the platform's capabilities extend to sarcopenia screening and fall risk assessment, addressing critical needs within an aging global demographic.

The growing demand for standardized, accurate tools for conditions like sarcopenia, exacerbated by an aging population, presents a significant market opportunity. Bluepoint Partners highlighted AIT Studio's unique ability to combine validated clinical accuracy with practical, widespread deployment across both leading hospitals and community health centers. This dual-track success underscores the platform's versatility and market readiness.

AIT Studio's CEO, Sinki Park, emphasized the company's commitment to enhancing the user experience and clinical utility of its medical devices. The focus remains on delivering a reliable and intuitive tool that demonstrably boosts productivity within clinical environments, ensuring seamless integration into healthcare workflows.